drugset / Trial / NCT00366938

Efficacy and Safety of Lumiracoxib in Patients With Knee Osteoarthritis (OA).

NCT00366938

Phase 3 Completed 1464 enrolled Novartis
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will investigate the efficacy and safety of lumiracoxib in patients with primary knee osteoarthritis (OA).

Timeline

Start
2003-09
Primary completion
2004-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Lumiracoxib Small molecule 100 mg

Indications